A bonanza of cardiology news!
Novartis’ new HPB drug, Tekturna, shows solid results used with Diovan.
Angiomax from The Medicines Company is effective in anti-clotting trial (anti-clotting is big news these days…)
Schering-Plough has promising results for its investigational blood thinner.
New heart failure drug: symptom relief, but no extended life (a single, but everyone still looking for the home run).
Curious result for potent Lilly experimental cholesterol drug – ho-hum efficacy.
Will antisense drugs finally break through? Maybe.
Stents, stents, and more stents! Abbott’s new experimental stent looks like a real winner – too bad it has such a non-intuitive name (Xience). Abbott also looks to score with the first absorbable (dissolving) stent. But here’s an interesting study result – angioplasty no more effective than drug therapy? That’s a potential clinical practice game-changer.
Pfizer appears to be losing out on some Norvasc patent life. This not only has positive ramifications for makers of generics, but also for Novartis, who has a combo drug using amlopidine teed up.
Accomplia, Sanofi’s new weight loss drug, seems to be on an approval treadmill. This article from the new Wall Street Journal Health blog, a new entry into the pharma blogosphere that is quite high-quality.